Secukinumab for the treatment of plaque psoriasis and psoriatic arthritis

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-012
• By: GARCíA GIMéNEZ, Ignacio ()
• Co-author(s): Mrs Isabel María Carrión Madroñal (Hospital Universitario Juan Ramón Jiménez, Huelva;, Spain)
  Ana Belén Guisado Gil, Pharmacy Department (Hospital Universitario Juan Ramón Jiménez, Huelva;, Spain)
  Ignacio García Giménez, Pharmacy Department (Hospital Universitario Juan Ramón Jiménez, Huelva;, Spain)
  Ernesto Sánchez Gómez, Pharmacy Department (Hospital Universitario Juan Ramón Jiménez, Huelva;, Spain)
  
• Abstract:

  KEYWORDS: PASI, psoriasis, psoriatic arthritis, secukinumab.
  
  BACKGROUND:
  Pivotal phase III randomized controlled trials have demonstrated promising efficacy and safety of secukinumab for the treatment of moderate-to-severe plaque psoriasis (PP) and psoriatic arthritis (PA). However, trial results might have limited external validity in daily..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login